Creative Biolabs is making significant strides in non-IgG antibody production, offering sophisticated solutions for IgE, IgM, and IgA antibody development that could transform immunotherapy research and pharmaceutical applications.
The company has developed specialized techniques for producing high-quality antibodies across multiple cell lines, including CHO, HEK293, and myeloma cells. Their proprietary recombinant DNA technology enables enhanced expression levels and stability for each antibody type.
For IgE antibodies, the company has optimized expression systems to address complex purification challenges. Using strategies like affinity chromatography and ion exchange chromatography, Creative Biolabs can generate high-purity IgE antibodies with potential applications in cancer, infectious disease, and inflammatory treatments.
In IgM antibody production, the company can manipulate pentameric and hexameric structures to ensure optimal biological activity. Their advanced purification methods, including three-step and two-step techniques, allow for high recovery rates that meet preclinical study standards.
The IgA antibody development platform focuses on monomeric and dimeric variations, with particular emphasis on mucosal immunity research. Utilizing techniques like lectin and peptide M affinity chromatography, the company can produce substantial quantities of purified IgA for fundamental studies and medicinal product development.
By providing scalable, high-quality non-IgG antibody solutions, Creative Biolabs is positioning itself at the forefront of immunotherapy research, potentially accelerating developments in targeted therapeutic approaches.
